基石药业将于ASH年会公布CS5001淋巴瘤适应症临床数据
财中社11月6日电基石药业-B（02616）发布公告，宣布将在第66届美国血液学会（ASH）年会上公布CS5001针对淋巴瘤的最新临床数据。ASH年会定于2024年12月7日至12月10日在美国加利福尼亚州圣地亚哥举行。CS5001是该公司的一款重磅产品，主要用于治疗晚期淋巴瘤。
根据初步数据，CS5001在所有剂量水平中，针对可评估的晚期B-细胞淋巴瘤患者的总体客观缓解率（ORR）达到43.5%。具体来看，CS5001针对晚期霍奇金淋巴瘤的ORR为60%，非霍奇金淋巴瘤的ORR为50%。公司还计划在ASH年会上详细公布更新的数据，并在全球范围内继续进行多中心I期试验及即将启动的Ib期剂量扩展研究。CS5001的开发和商业化已于2020年与LigaChem Biosciences, Inc.达成协议，基石药业获得了全球其他地区的独家开发权。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10